AXSOME THERAPEUTICS, INC. Cost of Revenue
AXSOME THERAPEUTICS, INC. (AXSM) reported Cost of Revenue of $5.20 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Expense Statement
us-gaap:CostOfRevenue · last filed 2023-02-28
- AXSOME THERAPEUTICS, INC. cost of revenue for the quarter ending 2022-12-31 was $2.30M.
- AXSOME THERAPEUTICS, INC. cost of revenue for the quarter ending 2022-09-30 was $1.90M.
- AXSOME THERAPEUTICS, INC. cost of revenue for the quarter ending 2022-06-30 was $1.00M, a 0.00% change year-over-year.
- AXSOME THERAPEUTICS, INC. cost of revenue for the quarter ending 2022-03-31 was $0.00.
- AXSOME THERAPEUTICS, INC. cost of revenue for fiscal 2022 was $5.20M.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2022-12-31 | $2.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $4.20M derived: sum of 2 quarters · filed 2023-02-28 | $5.20M derived: sum of 3 quarters · filed 2023-02-28 | $5.20M 10-K · filed 2023-02-28 |
| 2022-09-30 | $1.90M 10-Q · filed 2022-11-07 | $2.90M derived: sum of 2 quarters · filed 2022-11-07 | $2.90M 10-Q · filed 2022-11-07 | |
| 2022-06-30 | $1.00M 10-Q · filed 2022-08-09 | $0.00 10-Q · filed 2022-08-09 | ||
| 2022-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2023-02-28 | |||
| 2021-06-30 | $1.00M 10-Q · filed 2022-08-09 | $0.00 10-Q · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |